A Phase 1 interventional study of Dextromethorphan and Capivasertib in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the effect of capivasertib on the pharmacokinetics of oral dextromethorphan in healthy participants.
This is an open-label, fixed sequence study conducted at a single study centre.
The study will comprise of:
Period 2 (from Day 4 to Day 8): Participants will receive 2 doses of capivasertib and a single dose of dextromethorphan during this period.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of dextromethorphan in Period 1. After a minimum washout period of 4 days from the first dose of dextromethorphan, participants will receive the first dose of capivasertib, followed by a second dose of capivasertib after 12 hours, administered concomitantly with a single dose of dextromethorphan in Period 2.
Drug: Dextromethorphan · Drug: Capivasertib
Dextromethorphan will be administered orally once in Period 1 and once in Period 2
Capivasertib will be administered orally twice in Period 2
Area under concentration time curve from time 0 to infinity (AUCinf) of dextromethorphan
To evaluate the PK (AUCinf) of dextromethorphan when administered orally alone and following oral dosing of capivasertib
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) of dextromethorphan
To evaluate the PK (AUClast) of dextromethorphan when administered orally alone and following oral dosing of capivasertib
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Maximum observed drug concentration (Cmax) of dextromethorphan
To evaluate the PK (Cmax) of dextromethorphan when administered orally alone and following oral dosing of capivasertib
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) of capivasertib
To evaluate the PK (AUClast) of capivasertib following oral dosing
Time frame: Period 2: Day 5 to Day 8
Time to reach maximum observed concentration (tmax) of capivasertib
To evaluate the PK (tmax) of capivasertib following oral dosing
Time frame: Period 2: Day 5 to Day 8
Maximum observed drug concentration (Cmax) of capivasertib
To evaluate the PK (Cmax) of capivasertib following oral dosing
Time frame: Period 2: Day 5 to Day 8
Ratio of AUCinf following co-administration to AUCinf following dosing alone (R AUCinf) of dextromethorphan
To evaluate the PK (R AUCinf) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Ratio of AUClast following co-administration to AUClast following dosing alone (R AUClast) of dextromethorphan
To evaluate the PK (R AUClast) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Ratio of Cmax following co-administration to Cmax following dosing alone (R Cmax) of dextromethorphan
To evaluate the PK (R Cmax) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Terminal elimination half-life (t1/2λz) of dextromethorphan
To evaluate the PK (t1/2λz) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Terminal rate constant (λz) of dextromethorphan
To evaluate the PK (λz) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Time to reach maximum observed concentration (tmax) of dextromethorphan
To evaluate the PK (tmax) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Area under concentration time curve from time 0 to infinity (AUCinf) of metabolite (dextrorphan)
To evaluate the PK (AUCinf) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) of metabolite (dextrorphan)
To evaluate the PK (AUClast) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Maximum observed drug concentration (Cmax) of metabolite (dextrorphan)
To evaluate the PK (Cmax) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Ratio of AUClast following co-administration to AUClast following dosing alone (R AUClast) of metabolite (dextrorphan)
To evaluate the PK (R AUClast) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3, Period 2: Day 6 to Day 8
Terminal elimination half-life (t1/2λz) of metabolite (dextrorphan)
To evaluate the PK (t1/2λz) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Terminal rate constant (λz) of metabolite (dextrorphan)
To evaluate the PK (λz) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Time to reach maximum observed concentration (tmax) of metabolite (dextrorphan)
To evaluate the PK (tmax) of dextromethorphan following oral dosing
Time frame: Period 1: Day 1 to Day 3
Number of participants with adverse events (AEs) and serious AEs
To examine the safety and tolerability of capivasertib when administered with dextromethorphan
Time frame: Up to Day 16
Percentage change from baseline in bilirubin levels
To evaluate the effect of capivasertib dosing on total, conjugated, and unconjugated bilirubin levels
Time frame: Period 1: Day 1 to Day 2, Period 2: Day 4 to Day 7
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Mar 2026 to primary completion in Jul 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dextromethorphan · Capivasertib